| L |
|
L305V/S314E/K337A/F374Y-Factor VIIa has dramatically enhanced intrinsic activity
|
| Persson E., Bak H., Østergaard A., Olsen O. H. |
| |
|
Laboratory (on base coagulological tests) it is latent proceeding hematogenous thrombophilias
|
| Berkovskiy A. L., Orel E. B., Vasilyev S. A., Sergeeva E. V., Avdonin P. V., Gavrilova A. V., Rudakov V. E., Gorodetskiy V. M. |
| |
|
Laboratory assessment of acquired thrombophilia: current and past experience in Australasia with lupus anticoagulant (LA) and anti-cardiolipin antibody (ACA) testing
|
| Favaloro E. J., Bonar R., Silvestrini R., Smith J., Exner T., Low J., Lloyd J., Marsden K. |
| |
|
Laboratory diagnosis of congenital thrombophilia: current and past practice in Australia
|
| Favaloro E. J., Bonar R., Wheeler M., Low J., Aboud M., Duncan E., Smith J., Exner T., Lloyd J., Marsden K. |
| |
|
Laboratory diagnosis of von Willebrand Disorder: current and past practice in Australasia
|
| Favaloro E. J., Bonar R., Sioufi J., Hertzberg M., Street A., Lloyd J., Marsden K. |
| |
|
Laborious way to an efficient prophylaxis: Homozygous prothrombin G20210A mutation in a neonate with cardiac diverticulum
|
| Rauch R., Girisch M., Wiegand G., Hofbeck M. |
| |
|
Labrirhagin, a protein with metalloprotease and disintegrin domains from Trimeresurus albolabris venom, activates platelets by a mechanism involving GPVI, aIIbbIII3
|
| Doermann D., Navdaev A., Clemetson J. M., Kehrel B. E., Clemetson K. J. |
| |
|
Lack dose-response with Fondaparinux and Idraparinux is due to endogenous antithrombin saturation
|
| Hoppensteadt D., Walenga J., Jeske W., Fareed J. |
| |
|
Lack of a 2-antiplasmin promotes endothelial healing via over-release of VEGF after vascular injury in mice
|
| Matsuno H., Kozawa O., Okada K., Ueshima S., Matsuo O. |
| |
|
Lack of a2-antiplasmin promotes endothelial healing via over-release of VEGF after vascular injury in mice
|
| Matsuno H., Kozawa O., Okada K., Ueshima S., Matsuo O. |
| |
|
Lack of association between the annexin V gene -1C®T polymorphism and acute myocardial infarction in 150 young Italian women
|
| Spreafico M., Peyvandi F., Tagliabue L., Merlini P. A., Mannucci P. M. |
| |
|
Lack of association of platelet membrane glycoprotein polymorphisms with the clinical expression of von Willebrand disease type 1
|
| Pereira J., Quiroga T., Mezzano D., Pereira M. E., Morales M., Goycoolea M., Hidalgo P., Prieto C. |
| |
|
Lack of correlation between HPA1 polymorphism and ADP induced platelet activation: study of a large cohort of normal subjects
|
| Boval B., Gueguen R., Mazoyer E., Lepape M. T., Varsat B., Bal Dit Sollier C., Drouet L. |
| |
|
Lagrangian modeling of platelet adhesion and its application to experimental data
|
| Machin M., Mazzucato M., Cozzi M. R., De Marco L., Canu P. |
| |
|
LDL-receptor related protein (LRP) interacts with leukocyte integrin CD11b/CD18: a novel pathway in inflammatory regulation?
|
| Spijkers P. P. E. M., Westein E., Gahmberg C. G., Lenting P. J. |
| |
|
Left adrenal hemorrhage with intravascular coagulation- case report
|
| Koziri A., Koropouli M., Spanaki A.-M., Sfiraki N., Papagiannaki A., Daskalaki K., Filippidis M., Glampedaki M. |
| |
|
Legg-Perthe's disease and thrombophilia: a causal association?
|
| Balasa V. V., Gruppo R. A., Pillow A. G., Bekcer A., Stroop D., Glueck C. J., Wang P. |
| |
|
Lepirudin (Refludan®) prevents shigatoxin-induced hemorrhagic colitis/hemolytic uremic syndrome
|
| Raife T. J., Fenwick B. |
| |
|
Lepirudin anti-coagulation in critically ill patients with (suspected) heparin-induced thrombocytopenia and thrombosis
|
| Wester J. P. J., tEn cAte J., Oudemans-Van Straaten H. M., Bosman R. J., Van Der Spoel J. I., Zandstra D. F. |
| |
|
Leukocyte–platelet interaction: modulation by lipids of different density and inhibition by high dose of catecholamines
|
| Dovlatova N. L., Bouriachkovskaia L. I., Uchitel I. A., Masenko V. P. |
| |
|
Levels of anti-thrombin III activity in the plasma of cynomolgus monkeys after administration of recombinant human anti-thrombin III
|
| Fadin M., Boldrin M., Gavasso S., Zerbinati P., Tognin G., Bedendo S., Dedja A., Rigotti P., Girolami A., Simioni P., Cozzi E., Ancona E. |
| |
|
Levels of D-dimer do not predict deep venous thrombosis in medical–surgical ICU patients
|
| Crowther M., Cook D. J. C., Meade M., Rabbat C., Griffith L., Bates S. M., Guyatt G., Hanna S., Geerts W., Johnston M. |
| |
|
Levels of endothelial activation markers, D-dimer fragments and pro-inflammatory cytokines and sickle cell disease severity
|
| Schnog J., Brandjes D., Rojer R., Mac Gillavry M., Meijer J., Ten Cate H., Duits A. |
| |
|
Levels of plasma tissue activator plasminogen (tPA)- A useful marker in the differential diagnosis of chest pain (marker of plaque destabilization)
|
| Sfiridaki K., Tsoutsoumanou K., Dermitzakis A., Zaharaki A., Avramakis G., Meidanis K., Stratigakis G., Kandidaki E., Livadiotaki A., Nikolaidis G. |
| |
|
Levels of soluble tissue factor are related to future clinical events in patients with previous myocardial infarction
|
| Seljeflot I., Hurlen M., Arnesen H. |
| |
|
Life threatening mediastinal-retroperitoneal hemorrhage in a child with moderate hemophilia A and high titer inhibitor: successful management with recombinant activated factor VII
|
| Yilmaz S., Ören H., Irken G., Atabay B., Duman M., Yilmaz E., Çakmakçi H. |
| |
|
Life-threatening thrombosis following splenectomy in a patient with ITP: successful management with anticoagulation and danazol
|
| Preusser Tiede M., Jy W., Horstman L. L., Ahn Y. S. |
| |
|
Ligand binding to GP IIb–IIIa and stimulation of platelet release reactions
|
| Mauzurov A. V., Naimushin Y. A. |
| |
|
Ligand for peroxisome proliferator-activated receptor-a (PPARa) Down-regulates tumor necrosis factor - a-induced pro-coagulant activation of tissue factor through inhibition of ap-1-dependent gene transcription in human endothelial cells
|
| Horie S., Nagata K., Oida K., Ishii H., Matsuda J. |
| |
|
Ligneous conjunctivitis: report of two cases
|
| Contarini P., Araujo P., Sousa M. A. J., Oliveira M. H. C. F., Gadelha T. |
| |
|
Limited ability of nonactivated partial thromboplastin time to monitor clotting factors activation in high purity/high potency Factor IX concentrates
|
| Grancha S., Massot M., Jorquera J. I. |
| |
|
Limited exposure of phosphatidylserine on stimulated platelets is necessary for procoagulant activity and provides binding sites for lactadherin
|
| Gilbert G. E., Shi J., Rasmussen J. T., Heegaard C. W., Zhao J., Price P. |
| |
|
Limiting the parvovirus B19 load in manufacturing pools results in final containers of plasma derivatives nonreactive for parvovirus B19 genome
|
| Gröner A., Weimer T., Spyra M. |
| |
|
Lineage-specific correction of a hemorrhagic disorder affecting platelets: gene therapy for Glanzmann thrombasthenia
|
| Wilcox D. A., Hodivala-Dilke K. M., Johnson B. D., Hynes R. O., White G. C. |
| |
|
Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci
|
| De Visser M. C. H., Sandkuijl L. A., Lensen R. P. M., Vos H. L., Rosendaal F. R., Bertina R. M. |
| |
|
Lipid levels and homocysteine are determinants which influence the epinephrine–collagen- and ADP–collagen-closure time
|
| Zotz R., Gerhardt A., Scharf R. E. |
| |
|
Lipid Phosphate Phosphatase 1 (LPP1) regulates lysophosphatidic acid signaling in platelets
|
| Smyth S. S., Sigal Y., Pamuklar Z., Yong X., Prestwich G. D., Morris A. J. |
| |
|
Lipid rafts in platelet activation processes
|
| Payrastre B., Bodin S., Tronchere H., Gratacap M. P., Plantavid M. |
| |
|
Lipoprotein (a) levels and isoforms and fibrinolytic parameters in young survivors of myocardial infarction with and without peripheral artery disease
|
| Zorio E., Falcó C., España F., Osa A., Castelló R., Almenar L., Aznar J., Estellés A. |
| |
|
Lipoprotein (a) polymorphisms in Mexican-Amerindian populations
|
| De La Peña A., Cardoso-Saldaña G., Zamora-Gonzalez J., Posadas-Romero C., Malvido-Miranda E., Morales-Anduaga M. E., Gomez R., Hernandez B., Anglés-Cano E. |
| |
|
Lipoprotein A contributes to genetic risk for Venous Thrombosis and Arterial Stroke in U.S. Children
|
| Goldenberg N., Knapp-Clevenger R., Manco-Johnson M. |
| |
|
Local and clinical factors are the likely cause of venous thrombosis in lower limb arthroplasty
|
| Sharma A., Das Gupta A., Agarwala S., Bhagwat A., Khodaiji S., Dastur F. D. |
| |
|
Local blockade of the collagen binding domain to vWF-A3 with Saratin decreases thrombotic risk in human atherosclerotic lesions
|
| Badimon L., Juan O., Duran X., Casani L., Vilahur G. |
| |
|
Local blockade of vWF binding epitopes on damaged vessel wall exposed collagen with Saratin inhibits thrombotic risk at different hemodynamic conditions
|
| Vilahur G., Casani L., Duran X., Sánchez-Gómez S., Badimon L. |
| |
|
Local changes in coagulation and fibrinolysis in patients with a previous deep venous thrombosis
|
| Kolbach D. N., Van Oerle R., Hamulyák K., Neumann H. A. M., Prins M. H. |
| |
|
Localization and activity of ecto-ATP diphosphohydrolase/CD39 in human tissues
|
| Moriguchi S., Hatakeyama K., Marutsuka K., Matsumoto M., Yagi H., Sakurai Y., Fujimura Y., Asada Y. |
| |
|
Localized short-term myocardial ischemia causes massive coronary t-PA release
|
| Aspelin T., Eriksen M., Lindgaard A. K., Lyberg T., Ilebekk A. |
| |
|
Long term prophylaxis in VWD
|
| Berntrop E. |
| |
|
Long-term in vivo platelet presensitization may explain the mechanism of factor VIIa prophylaxis in factor VII-deficient patients
|
| Van Heerde W., Verbruggen H., Lourenssen G. J. A. C. M., Novakova I. R. O. |
| |
|
Long-term clinical outcome of patients with pulmonary embolism: a prospective, multicenter study
|
| Becattini C., Agnelli G., Prandoni P., Silingardi M., Taliani M. R., Miccio M., Imberti D., Poggio R., Ageno W., Pogliani E., Porro F., Zonzin P., Bertoldi A., Tomasi C., Casazza F., Ria L., Moia M., Ambrosio G. B., Piovella F., De Lucia D., Pieralli F. |
| |
|
Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremities: survival, risk factors and post–thrombotis syndrome
|
| Baarslag H., Koopman M. M. W., Hutten B. A., Linthorst Homan M. W., Buller H. R., Reekers J. A., Van Beek E. J. R. |
| |
|
Long-term outcomes following recovery from thrombotic thrombocytopenic purpura – hemolytic uremic syndrome (TTP-HUS) measured by health-related quality-of-life (QOL) assessments
|
| Terrell D. R., Vesely S., Perdue J. J., Howard M. A., Lammle B., George J. N. |
| |
|
Long-term prophylaxis with FEIBA® in patients with high-responding inhibitors
|
| Escuriola Ettingshausen C., Martinez Saguer I., Funk M. B., Klarmann D., Stoll H., Biller R., Kreuz W. |
| |
|
Long-term RAGE-mediated NF-kB activation in diabetic neuropathy and its role in loss of pain perception
|
| Bierhaus A., Haselbeck M., Humpert P. M., Liliensiek B., Dehmer T., Morcos M., Sayed A. A. R., Schulz J. B., Heuss D., Neundörfer B., Tritschler H., Schmidt A. M., Schwaninger M., Schleicher E., Stern D. M., Arnold B., Nawroth P. P. |
| |
|
Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE)
|
| Lee A. Y. Y., Levine M. N., Baker R. I., Bowden C., Kakkar A. K., Prins M., Rickles F. R., Julian J. A., Haley S., Kovacs M. J., Gent M. |
| |
|
Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with nonmetastatic malignancy and venous thromboembolism (VTE)
|
| Lee A. Y. Y., Julian J. A., Levine M. N., Baker R. I., Bowden C., Kakkar A. K., Prins M., Rickles F. R., Gent M. |
| |
|
Long-term, low-intensity warfarin for the prevention of recurrent venous thromboembolism: the PREVENT trial
|
| Ridker P., Goldhaber S., Glynn R. |
| |
|
Loss of stability of the baseline state and the coagulation triggering: a mathematical modeling study
|
| Khanin M. A., Rakov D. V. |
| |
|
Loss of tolerance for platelet glycoprotein VI by vaccination of Balb/c mice with a GPVI-tetanus toxoid fusion protein
|
| Wilson E., Harmer I., Ouwehand W. |
| |
|
Low detection rate of antibodies to nonfunctional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay
|
| Ling M., Duncan E. M., Rodgers S. E., Street A. M., Lloyd J. V. |
| |
|
Low inhibitor levels allow fast and sufficient thrombin generation in tissue factor-activated cord plasma
|
| Cvirn G., Gallistl S., Juergens G., Muntean W. |
| |
|
Low intensity ultrasound increases endothelial cell nitric oxide synthase activity
|
| Altland O., Suchkova V. N., Sahni A., Francis C. W. |
| |
|
Low molecular heparin in prophylaxis of thrombohamorragic complications after caesarean delivery in patients with cardiologic deseases
|
| Makatsaria A., Babessa R. F., Marov S. V. |
| |
|
Low molecular weight heparin (LMWH) in pregnant women with mechanical prosthetic heart valves (MPHV)
|
| Meschengieser S. S., Salviu M. J., Sanchez Luceros A., Casais P., Hendler M. F., Turdo K., Lazzari M. A. |
| |
|
Low molecular weight heparin therapy in neonatal cerebral sinovenous thrombosis: a consecutive cohort study
|
| Deveber G., Chan A. K., Shroff M., Macgregor D. L., Massicotte M. P., Curtis R. M., Adams M. M. |
| |
|
Low molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anti-coagulants
|
| Iorio A., Guercini F., Conti S., Pini M. |
| |
|
Low vitamin B6, markers of inflammation, and coronary artery disease
|
| Friso S., Girelli D., Martinelli N., Olivieri O., Pizzolo F., Bozzini C., Lotto V., Faccini G., Beltrame F., Selhub J., Corrocher R. |
| |
|
Lower activation of circulating platelets after implantation of Toyobo LVAS was associated with lower incidence of thromboembolism: a comparison with Novacor LVAS
|
| Murasaki S., Murasaki K., Tanoue K., Kawana M., Kasanuki H. |
| |
|
Lower degree of protein C activation in protein C deficient individuals of a large kindred with type I PC deficiency, as measured by the level of APC-PCI complex
|
| Vossen C., Van Korlaar I., Rosendaal F., Naud S. J., Callas P. W., Long G. L., Bovill E. |
| |
|
Lower limb trauma is associated with a moderate risk of thrombosis caused by sustained release of tissue factor despite early functional mobilization
|
| Kaiser P., Prechel M., Hoppensteadt D., Bacher P., Misselwitz F., Lassen M. R., Walenga J. M. |
| |
|
Low-molecular weight heparin (LMWH) enoxaparin counteracts the expression of endothelial cell tissue factor elicited by malignant cells
|
| Marchetti M., Vignoli A., Agosti M., Falanga A. |
| |
|
Low-molecular weight heparin therapy and survival in patients with malignant disease
|
| Kakkar A., Levine M. N., Kadziola Z., Low V., Patel H., Williamson R. C. N., Lemoine N. R. |
| |
|
Low-molecular weight heparins (LMWH) modulate the functional adhesion of tumor cells to the vascular endothelium
|
| Vignolo A., Marchetti M., Agosti M., Falanga A. |
| |
|
Low-molecular-weight heparin (LMWH) as bridging anticoagulation in patients who require temporary interruption of warfarin for elective surgery: assessment of a standardized perioperative anticoagulation regimen
|
| Douketis J., Johnson J. A., Turpie A. G. G. |
| |
|
Low-molecular-weight heparin dose requirements are age-related through childhood
|
| Manco-Johnson M., Graham D., Valentino L., Knapp-Clevenger R. |
| |
|
Low-molecular-weight heparin is as effective and safe as unfractionated heparin for the initial treatment of pulmonary embolism: a meta-analysis
|
| Quinlan D. J., Mcquillan A., Eikelboom J. W. |
| |
|
LPS induced MMPs release in mice: role of platelets and inhibition by NCX4016 (nitroaspirin)
|
| Falcinelli E., Momi S., Del Soldato P., Gresele P. |
| |
|
LPS-activation of THP-1 cells: effect of anti-thrombin studied by in vivo footprinting of the tissue factor (TF) gene promoter
|
| Freyburger G., Labrouche S., Reboul M. P., Dali F. |
| |
|
LRP mediated catabolism of factor VIII
|
| Saenko E. |
| |
|
Lupus anticoagulant and elevated anticardiolipin antibodies as risk factors for venous thromboembolism
|
| Windyga J., Bykowska K., Lopaciuk S. |
| |
|
Lupus anticoagulant as marker of immune system dysfunction in patients with multiple sclerosis
|
| Minullina I., Tsybulkin A., Arleevskaya M. |
| |
|
Lupus anticoagulant in systemic lupus erythematodes as risk factor for cryptogenic stroke
|
| Kahles T., Humpich M., Sitzer M., Lindhoff-Last E. |
| |
|
Lysophosphatidylcholine induction of chemokines in human microvascular endothelial cells is dependent on the activation of MAP kinases and PI3 kinase
|
| Murugesan G., Rani M. R. S., Gerber C. E., Ransohoff R. M., Chisolm G. M., Kottke-Marchant K. |
| |
|
Lysosomal beta-N-acetylhexosaminidase is a primer of platelet activation
|
| Rossi R., Giannini S., Mencarelli S., Orlacchio A., Emiliani C., Gresele P. |
| |
